The guidance implements new provisions added to the Federal Food, Drug, and Cosmetic Act in the Drug Quality and Security Act in which Congress created a new statutory category of "outsourcing facilities" that compound human drugs. New section 503B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353b) allows compounders to register with FDA as outsourcing facilities, and the draft guidance discusses the process for the registration of outsourcing facilities.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.